Publications
Detailed Information
Adiponectin is a potential catabolic mediator in osteoarthritis cartilage
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Eun Ha | - |
dc.contributor.author | Lee, Yun Jong | - |
dc.contributor.author | Kim, Tae Kyun | - |
dc.contributor.author | Chang, Chong Bum | - |
dc.contributor.author | Shin, Kichul | - |
dc.contributor.author | Lee, Eun Bong | - |
dc.contributor.author | Song, Yeong Wook | - |
dc.contributor.author | Lee, Eun Young | - |
dc.contributor.author | Chung, Jin-Haeng | - |
dc.date.accessioned | 2012-05-29T06:04:32Z | - |
dc.date.available | 2012-05-29T06:04:32Z | - |
dc.date.issued | 2010 | - |
dc.identifier.citation | ARTHRITIS RESEARCH & THERAPY; Vol.12 6; - | ko_KR |
dc.identifier.issn | 1478-6354 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76545 | - |
dc.description.abstract | Introduction: Adiponectin has been implicated in the pathogenesis of osteoarthritis (OA). We studied the effects of adiponectin on the OA cartilage homeostasis. Methods: Immunohistochemical analysis was performed to evaluate differential expression of adiponectin receptors (AdipoRs) in nonlesional and lesional areas of OA cartilage. Cartilage and chondrocytes from the knee joints of primary OA patients were cultured in the presence of adiponectin (0 similar to 30 mu g/ml). The levels of total nitric oxide (NO), matrix metalloproteinase (MMP)-1, -3, and -13, and tissue inhibitor of metalloproteinase (TIMP)-1 were measured in the conditioned media. The levels of inducible NO synthase (iNOS) and MMPs were determined with the quantitative real-time reverse transcription-polymerase chain reaction. The concentrations of collagenase-cleaved type II collagen neoepitope (C1-2C) were determined in the supernatant of adiponectin-stimulated OA cartilage explants. The effects of kinase and NOS inhibitors were evaluated in the adiponectin-stimulated chondrocytes. Results: The expression levels of both AdipoR1 and AdipoR2 were significantly higher in lesional than in nonlesional areas of OA cartilage. The increased rate of AdipoR1-positive chondrocytes was twice that of AdipoR2-positive chondrocytes when compared between nonlesional and lesional areas. Adiponectin-stimulated OA chondrocytes showed increased total NO and MMP-1, -3, and -13 levels compared with nonstimulated cells. The TIMP-1 level was not affected. The C1-2C levels were increased by adiponectin in OA cartilage explant culture. AMP-activated protein kinase (AMPK) and c-Jun N-terminal kinase (JNK) inhibitors (compound C and SP600125) significantly suppressed adiponectin-induced production of total NO and MMP-1, -3, and -13. Inducible NOS inhibitors enhanced the expression of the adiponectin-induced MMPs. Conclusions: Adiponectin causes matrix degradation in OA cartilage and increases MMPs and iNOS expression via the AMPK and JNK pathways in human OA chondrocytes. The catabolic effects of adiponectin may be counteracted by NO. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BIOMED CENTRAL LTD | ko_KR |
dc.title | Adiponectin is a potential catabolic mediator in osteoarthritis cartilage | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 강은하 | - |
dc.contributor.AlternativeAuthor | 이윤종 | - |
dc.contributor.AlternativeAuthor | 김태균 | - |
dc.contributor.AlternativeAuthor | 장종범 | - |
dc.contributor.AlternativeAuthor | 정진행 | - |
dc.contributor.AlternativeAuthor | 신기철 | - |
dc.contributor.AlternativeAuthor | 이은영 | - |
dc.contributor.AlternativeAuthor | 이은봉 | - |
dc.contributor.AlternativeAuthor | 송영욱 | - |
dc.identifier.doi | 10.1186/ar3218 | - |
dc.citation.journaltitle | ARTHRITIS RESEARCH & THERAPY | - |
dc.description.citedreference | Saxena NK, 2010, GASTROENTEROLOGY, V139, P1762, DOI 10.1053/j.gastro.2010.07.001 | - |
dc.description.citedreference | Challa TD, 2010, MOL CELL ENDOCRINOL, V323, P282, DOI 10.1016/j.mce.2010.03.025 | - |
dc.description.citedreference | Nishitani K, 2010, J CELL BIOCHEM, V109, P425, DOI 10.1002/jcb.22421 | - |
dc.description.citedreference | HAO D, 2010, RHEUMATOL INT | - |
dc.description.citedreference | Laurberg TB, 2009, J RHEUMATOL, V36, P1885, DOI 10.3899/jrheum.080907 | - |
dc.description.citedreference | Song HJ, 2009, TRANSL RES, V154, P18, DOI 10.1016/j.trsl.2009.04.003 | - |
dc.description.citedreference | Huang CY, 2009, EUR J CLIN INVEST, V39, P417, DOI 10.1111/j.1365-2362.2009.02106.x | - |
dc.description.citedreference | Filkova M, 2009, ANN RHEUM DIS, V68, P295, DOI 10.1136/ard.2008.095737 | - |
dc.description.citedreference | Yamauchi T, 2008, INT J OBESITY, V32, pS13, DOI 10.1038/ijo.2008.233 | - |
dc.description.citedreference | Lago R, 2008, OSTEOARTHR CARTILAGE, V16, P1101, DOI 10.1016/j.joca.2007.12.008 | - |
dc.description.citedreference | Lee YM, 2008, BIOCHEM BIOPH RES CO, V370, P641, DOI 10.1016/j.bbrc.2008.04.003 | - |
dc.description.citedreference | Hattori Y, 2008, FEBS LETT, V582, P1719, DOI 10.1016/j.febslet.2008.04.037 | - |
dc.description.citedreference | Haugen F, 2007, ENDOCRINOLOGY, V148, P5478, DOI 10.1210/en.2007-0370 | - |
dc.description.citedreference | Tang CH, 2007, J IMMUNOL, V179, P5483 | - |
dc.description.citedreference | Schober F, 2007, BIOCHEM BIOPH RES CO, V361, P968, DOI 10.1016/j.bbrc.2007.07.106 | - |
dc.description.citedreference | Aigner T, 2007, NAT CLIN PRACT RHEUM, V3, P391, DOI 10.1038/ncprheum0534 | - |
dc.description.citedreference | Legendre F, 2007, CLIN EXP RHEUMATOL, V25, P546 | - |
dc.description.citedreference | Sharma L, 2007, ANN RHEUM DIS, V66, P141, DOI 10.1136/ard.2006.059931 | - |
dc.description.citedreference | Pottie P, 2006, ANN RHEUM DIS, V65, P1403, DOI 10.1136/ard.2006.061994 | - |
dc.description.citedreference | Chen TH, 2006, BBA-MOL BASIS DIS, V1762, P711, DOI 10.1016/j.bbadis.2006.06.008 | - |
dc.description.citedreference | Presle N, 2006, OSTEOARTHR CARTILAGE, V14, P690, DOI 10.1016/j.joca.2006.01.009 | - |
dc.description.citedreference | Neumeier M, 2006, J LEUKOCYTE BIOL, V79, P803, DOI 10.1189/jlb.0905521 | - |
dc.description.citedreference | Luo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021 | - |
dc.description.citedreference | Miyazaki T, 2005, BIOCHEM BIOPH RES CO, V333, P79, DOI 10.1016/j.bbrc.2005.05.076 | - |
dc.description.citedreference | Ho LJ, 2005, BIOCHEM PHARMACOL, V70, P200, DOI 10.1016/j.bcp.2005.04.039 | - |
dc.description.citedreference | Kadowaki T, 2005, ENDOCR REV, V26, P439, DOI 10.1210/er.2005-0005 | - |
dc.description.citedreference | Meier U, 2004, CLIN CHEM, V50, P1511, DOI 10.1373/clinchem.2004.032482 | - |
dc.description.citedreference | Englund M, 2004, ARTHRITIS RHEUM, V50, pS254 | - |
dc.description.citedreference | Schaffler A, 2003, JAMA-J AM MED ASSOC, V290, P1709 | - |
dc.description.citedreference | Tsao TS, 2002, J BIOL CHEM, V277, P29359, DOI 10.1074/jbc.C200312200 | - |
dc.description.citedreference | Wang Y, 2002, J BIOL CHEM, V277, P19521, DOI 10.1074/jbc.M200601200 | - |
dc.description.citedreference | Cooper C, 2000, ARTHRITIS RHEUM, V43, P995 | - |
dc.description.citedreference | Chan ED, 1998, BIOCHEM BIOPH RES CO, V253, P790 | - |
dc.description.citedreference | Hauselmann HJ, 1998, J IMMUNOL, V160, P1444 | - |
dc.description.citedreference | StefanovicRacic M, 1997, J ORTHOPAED RES, V15, P442 | - |
dc.description.citedreference | Tamura T, 1996, ENDOCRINOLOGY, V137, P3729 | - |
dc.description.citedreference | StefanovicRacic M, 1996, J IMMUNOL, V156, P1213 | - |
dc.description.citedreference | MURRELL GAC, 1995, BIOCHEM BIOPH RES CO, V206, P15 | - |
dc.description.citedreference | REGINATO AM, 1994, ARTHRITIS RHEUM, V37, P1338 | - |
dc.description.citedreference | HART DJ, 1993, J RHEUMATOL, V20, P331 | - |
dc.description.citedreference | FELSON DT, 1992, ANN INTERN MED, V116, P535 | - |
dc.description.tc | 9 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.